质子放疗作为提高体尾部局部晚期胰腺癌生存率的治疗策略:一项回顾性研究
该回顾性研究分析了2009年2月至2021年1月在兵库离子束医学中心接受质子放疗的200例体尾部局部晚期胰腺癌患者,中位总生存期为18.4个月,1年和2年总生存率分别为69.6%和35.4%。多因素分析显示肠系膜上动脉侵犯、CA19-9≥231.9 U/mL、胰前侵犯及未完成预定同步化疗是总生存的不良预后因素,且这些因素与更差的无远处转移生存相关。作者认为质子放疗可能是体尾部局部晚期胰腺癌有价值的多学科治疗选择。
要点
- 200例体尾部局部晚期胰腺癌质子放疗后中位总生存期18.4个月,1年与2年总生存率分别为69.6%与35.4%。
- 肠系膜上动脉侵犯、CA19-9≥231.9 U/mL、胰前侵犯及未完成预定同步化疗与更差总生存相关。
- 有预后因素者无远处转移生存统计学更差,提示远处转移对总生存影响显著。
核心结论
- 质子放疗用于体尾部局部晚期胰腺癌可能是有价值的多学科治疗选择。
- 伴肠系膜上动脉侵犯、质子放疗前血清CA19-9水平较高、胰前侵犯或未完成预定同步化疗的患者总生存更差,归因于无远处转移生存更差,提示远处转移对这类患者的总生存有显著影响。
研究设计与样本
- 回顾性分析2009年2月至2021年1月在兵库离子束医学中心接受质子放疗的200例体尾部局部晚期胰腺癌患者的病历资料,以确定 contribute 长期生存的预后因素。
- 试验注册:回顾性注册。
主要发现
- 质子放疗后1年和2年总生存率分别为69.6%和35.4%,中位总生存期为18.4个月。
- 1年和2年局部无进展生存率分别为84.3%和68.0%,1年和2年无进展生存率分别为44.3%和19.4%。
- 多因素分析中,肠系膜上动脉侵犯(仅肠系膜上动脉侵犯 vs 仅腹腔干侵犯,P=0.049;肠系膜上动脉合并腹腔干侵犯 vs 仅腹腔干侵犯,P=0.017)、CA19-9水平≥231.9 U/mL(P=0.001)、胰前侵犯(P=0.006)及未完成预定同步化疗(P=0.009)是总生存的统计学显著预后因素。
- 局部无进展生存无显著差异;但有预后因素者的无远处转移生存较无预后因素者统计学更差。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term outcomes and prognostic factors of proton radiotherapy for locally advanced pancreatic cancer (LAPC) in the body and tail are still unknown. The aim of this study was to determine the prognostic factors after proton radiotherapy in a large group of patients with LAPC in the body and tail. METHODS: The medical records of 200 patients with LAPC in the body and tail who underwent proton radiotherapy between February 2009 and January 2021 at the Hyogo Ion Beam Medical Center were retrospectively reviewed to identify prognostic factors that contribute to long-term survival. RESULTS: The overall survival rate at 1- and 2-year after PT was 69.6% and 35.4% with a median overall survival of 18.4 months. The 1- and 2-year local progression-free, and progression-free survival rates were 84.3% and 68.0%, and 44.3% and 19.4%, respectively. In multivariate analysis, superior mesenteric artery (SMA) invasion (SMA only invasion vs. celiac artery only invasion; P = 0.049: SMA and celiac artery invasion vs. celiac artery only invasion; P = 0.017), carbohydrate antigen 19-9 (CA 19-9) level ≥ 231.9 U/mL (P = 0.001), anterior peripancreatic invasion (P = 0.006), and incomplete scheduled concurrent chemotherapy (P = 0.009) were statistically significant prognostic factors for overall survival. There was no significant difference in local progression-free survival; however, distant metastasis-free survival was statistically worse in patients with prognostic factors than in those without. CONCLUSIONS: Proton radiotherapy for LAPC in the body and tail may be a valuable multidisciplinary treatment option. Patients with SMA invasion, higher pre-proton radiotherapy serum CA 19-9 level, anterior peripancreatic invasion, or incomplete scheduled concurrent chemotherapy had worse overall survival because of worse distant metastasis-free survival, suggesting that distant metastases have a significant impact on overall survival in such patients. TRIAL REGISTRATION: Retrospectively registered.
引用
- Ami K, Terashima K, Ishida J, et al. Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study. Radiat Oncol. 2023. PMID: 37553705. doi:10.1186/s13014-023-02301-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。